Decline of the Red Blood Cell Count in Patients Receiving Androgen Deprivation Therapy for Localized Prostate Cancer: Impact of ADT on Insulin-like Growth Factor-1 and Erythropoiesis

Urology

Volumn 75, Issue 6, 2010, Pages 1441-1445

  Hara, Noboru ^a   Nishiyama, Tsutomu ^a   Takizawa, Itsuhiro ^a   Saito, Toshihiro ^b   Kitamura, Yasuo ^b   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; ERYTHROPOIETIN; FLUTAMIDE; GOSERELIN; GROWTH HORMONE; INTERLEUKIN 6; SOMATOMEDIN C;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GROWTH HORMONE BLOOD LEVEL; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SIDE EFFECT;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; COHORT STUDIES; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SOMATOMEDINS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77952745975     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.11.021     Document Type: Article

References (24)

1. Greenspan S.L., Coates P., Sereika S.M., et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90 (2005) 6410-6417
2. Pinkawa M., Fischedick K., Piroth M.D., et al. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. Urology 69 (2007) 129-133
3. Nishiyama T., Ishizaki F., Anraku T., et al. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90 (2005) 657-660
4. Levy M.E., Perera S., van Londen G.J., et al. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology 71 (2008) 735-739
5. Alibhai S.M., Rahman S., Warde P.R., et al. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 68 (2006) 126-131
6. Nilsson-Ehle H., Jagenburg R., Landahl S., et al. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 65 (2000) 297-305
7. Daughaday W.H., and Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10 (1989) 68-91
8. Chahal H.S., and Drake W.M. The endocrine system and ageing. J Pathol 211 (2007) 173-180
9. Moromisato D.Y., Roberts Jr. C., Brasel J.A., et al. Erythrocyte insulin-like growth factor-L binding in younger and older males. Clin Endocrinol (Oxford) 48 (1998) 339-345
10. Masala A., Atzeni M.M., Alagna S., et al. Growth hormone secretion in polytransfused prepubertal patients with homozygous beta-thalassemia. Effect of long-term recombinant GH (recGH) therapy. J Endocrinol Invest 26 (2003) 623-628
11. Vihervuori E., Virtanen M., Koistinen H., et al. Hemoglobin level is linked to growth hormone-dependent proteins in short children. Blood 87 (1996) 2075-2081
12. Sohmiya M., and Kato Y. Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency. Clin Endocrinol (Oxford) 55 (2001) 749-754
13. Christ E.R., Cummings M.H., Westwood N.B., et al. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab 82 (1997) 2985-2990
14. Isahaya E, Hara N, Nishiyama T, et al. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. Prostate, in press.
15. Janssen J.A., Wildhagen M.F., Ito K., et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 89 (2004) 4391-4396
16. Miyagawa S., Kobayashi M., Konishi N., et al. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br J Haematol 109 (2000) 555-562
17. Kling P.J., Taing K.M., Dvorak B., et al. Insulin-like growth factor-I stimulates erythropoiesis when administered enterally. Growth Factors 24 (2006) 218-223
18. Gutiérrez S., Mukdsi J.H., Aoki A., et al. Ultrastructural immunolocalization of IGF-1 and insulin receptors in rat pituitary culture: evidence of a functional interaction between gonadotroph and lactotroph cells. Cell Tissue Res 327 (2007) 121-132
19. Huang Y.S., Rousseau K., Le Belle N., et al. Insulin-like growth factor-I stimulates gonadotrophin production from eel pituitary cells: a possible metabolic signal for induction of puberty. J Endocrinol 159 (1998) 43-52
20. Nelson A.E., Howe C.J., Nguyen T.V., et al. Erythropoietin administration does not influence the GH-IGF axis or makers of bone turnover in recreational athletes. Clin Endocrinol (Oxford) 63 (2005) 305-309
21. Lee P., Gelbart T., Waalen J., et al. The anemia of ageing is not associated with increased plasma hepcidin levels. Blood Cells Mol Dis 41 (2008) 252-254
22. Anawalt B.D., and Merriam G.R. Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metab Clin North Am 30 (2001) 647-669
23. Sommers B.D., Beard C.J., D'Amico A.V., et al. Somatopause: dismetabolic and bone effects. J Endocrinol Invest 28 (2005) 36-42
24. Hero M., Wickman S., Hanhijärvi R., et al. Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen. J Pediatr 146 (2005) 245-252